Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aspirin resistance-related GPIIIa gene polymorphic site and application

An aspirin and gene technology, applied in the field of medical disease treatment drug selection, can solve problems such as gene polymorphism uncertainty, and achieve the effect of reducing the recurrence rate of stroke

Inactive Publication Date: 2015-10-07
武汉欧瑞康安生物科技有限公司
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to incomplete statistics, clinical aspirin resistance is as high as 40% of patients, but because there are many targets that affect the action of aspirin, so far, the gene polymorphisms related to aspirin resistance are still uncertain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aspirin resistance-related GPIIIa gene polymorphic site and application
  • Aspirin resistance-related GPIIIa gene polymorphic site and application
  • Aspirin resistance-related GPIIIa gene polymorphic site and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Discovery of GPⅢa gene polymorphism (A1166C) associated with aspirin resistance:

[0028] The data of stroke patients from 2010 to 2014 were retrieved from the stroke database, and according to the diagnostic criteria of ischemic stroke, patients diagnosed with ischemic stroke were screened, and aspirin was further selected for secondary prevention (secondary prevention is for patients with cerebral palsy). For patients with stroke symptoms or after stroke, these people need to prevent reoccurrence of stroke) as the total sample (5033 people in total).

[0029] 1. Determine the number of people with stroke recurrence in the total sample, and explore the relationship between the polymorphism of the GPⅢa(A1166C) gene and stroke recurrence in the total sample (Table 2);

[0030] 2. In the total sample, patients who returned to the hospital for follow-up visits (including those who have relapsed and those who have not relapsed, a total of 3429 people), collected peripheral ...

Embodiment 2

[0046] Application of primers for GPⅢa gene polymorphism site (A1166C) related to aspirin resistance in the preparation of kits for screening aspirin resistance patients:

[0047] All patients with ischemic stroke for the first time were given aspirin for secondary prevention, and the patients were followed up 3 months later to detect the ARU and stroke recurrence of each patient. At the same time, the peripheral blood of the patients was collected to detect the presence of GPⅢa (A1166C) polymorphism by gene sequencing, and the incidence of aspirin resistance in mutant and wild-type patients was analyzed.

[0048]The study began in August 2013, and the deadline for case inclusion was August 2014. According to the diagnostic criteria for ischemic stroke, patients diagnosed with ischemic stroke were selected as the research objects, and the following tasks were completed:

[0049] 1. According to the secondary prevention guidelines of ischemic stroke and TIA, aspirin was given t...

Embodiment 3

[0059] Discovery of the P2Y1 gene polymorphism (A745G) associated with aspirin resistance:

[0060] Using the same stroke database, blood samples and methods as in Example 1, detect the relationship between the polymorphism of the P2Y1 (A745G) gene and stroke recurrence in the total sample (a total of 5033 people, the sample is the same as in Example 1) (Table 6); and The relationship between the polymorphism of the P2Y1 (A745G) gene and ARU≥550 in patients returning to the hospital for follow-up (including relapsed and non-relapsed patients, a total of 3429 people, the same as in Example 1) (Table 5).

[0061] The results showed that among patients with ischemic stroke who took aspirin for secondary prevention, compared with wild-type patients, the ARU value of aspirin response unit in P2Y1(A745G) mutant group was significantly higher, and the number of patients with ARU≥550 was significantly higher than that in wild-type patients. Type group (Table 5); at the same time strok...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an aspirin resistance-related GPIIIa gene polymorphic site and an application. An antiplatelet drug (particularly aspirin) plays a crucial role in the prevention of ischemic stroke; however, current investigation results indicate that many ischemic stroke patients taking the antiplatelet drug still suffer relapse of stroke even, and the phenomenon is called antiplatelet drug resistance. The applicant defines an aspirin resistance-related GPIIIa gene polymorphic site GPIIIa (A1166C) and designs a primer for detecting the site polymorphism for the site, wherein the primer can be used for preparing a kit for screening aspirin resistant patients so as to select an antiplatelet drug for ischemic stroke patients and reduce the aspirin resistance and stroke relapse.

Description

technical field [0001] The invention relates to the field of drug selection for medical disease treatment, in particular to the polymorphic site of GPⅢa gene related to aspirin resistance and its application. technical background [0002] With the aging population in our country, the incidence of cerebrovascular disease is increasing year by year. The latest survey results show that cerebrovascular disease has become the number one killer of Chinese people beyond tumors since 2010. There are 2 million new cases in my country every year. Chronic cerebrovascular disease accounts for 70-80%, recurrent patients account for 27%, and 70% of patients have neurological deficits. The high mortality rate, disability rate and recurrence rate of cerebrovascular disease have caused a great social burden and economic burden. burden. Antiplatelet drugs (especially aspirin) play a vital role in the prevention and treatment of cerebrovascular diseases, but the current survey results show that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6876C12Q2600/136C12Q2600/156
Inventor 胡波毛玲夏远鹏贺权威靳慧娟李亚男
Owner 武汉欧瑞康安生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com